Gupta S, Sharma A, Shukla A, Mishra A, Singh A
Invest New Drugs. 2025; .
PMID: 40014234
DOI: 10.1007/s10637-025-01513-y.
Yarawsky A, Ronau J, Thibaudeau T, Ehlinger A, Chhor G, Hyman S
Eur Biophys J. 2025; .
PMID: 39961810
DOI: 10.1007/s00249-025-01735-1.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S
Nat Commun. 2025; 16(1):1041.
PMID: 39863584
PMC: 11762753.
DOI: 10.1038/s41467-025-56318-7.
Xing Y, Zhao K, Zhang Y, Wang Y
Front Oncol. 2025; 14():1463505.
PMID: 39777345
PMC: 11703922.
DOI: 10.3389/fonc.2024.1463505.
Biggs G, Cawood E, Vuorinen A, McCarthy W, Wilders H, Riziotis I
Nat Commun. 2025; 16(1):73.
PMID: 39746958
PMC: 11697256.
DOI: 10.1038/s41467-024-55057-5.
Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors.
Ficarro S, Marto Z, Girardi N, Deng D, Maisonet I, Adelmant G
SLAS Discov. 2024; 29(8):100198.
PMID: 39622293
PMC: 11702861.
DOI: 10.1016/j.slasd.2024.100198.
Toxicity and Dermatokinetic Analysis of Ibrutinib in Human Skin Models.
Souto-Silva M, Bispo E, Albuquerque L, Barcelos S, Garcez E, Quilici L
Pharmaceutics. 2024; 16(11).
PMID: 39598501
PMC: 11597583.
DOI: 10.3390/pharmaceutics16111377.
Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin.
Li P, Liu D, Gao P, Yuan M, Zhao Z, Zhang Y
Cancer Innov. 2024; 4(1):e151.
PMID: 39544722
PMC: 11560382.
DOI: 10.1002/cai2.151.
The Immunomodulatory Mechanisms of BTK Inhibition in CLL and Beyond.
Jiang Q, Peng Y, Herling C, Herling M
Cancers (Basel). 2024; 16(21).
PMID: 39518015
PMC: 11545099.
DOI: 10.3390/cancers16213574.
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.
Bravo-Gonzalez A, Alasfour M, Soong D, Noy J, Pongas G
Cancers (Basel). 2024; 16(20).
PMID: 39456530
PMC: 11506569.
DOI: 10.3390/cancers16203434.
Synthesis of Radiopharmaceuticals "In-Loop" C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase.
Donnelly D, Preshlock S, Kaur T, Tran T, Wilson T, Mhanna K
Front Nucl Med. 2024; 1:820235.
PMID: 39355640
PMC: 11440948.
DOI: 10.3389/fnume.2021.820235.
Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads.
Dong S, Huang H, Li J, Li X, Jacob Bunu S, Yang Y
Commun Chem. 2024; 7(1):201.
PMID: 39251816
PMC: 11385544.
DOI: 10.1038/s42004-024-01279-z.
Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
Turner T, Brun P, Gruber R, Ofengeim D
Drugs R D. 2024; 24(2):263-274.
PMID: 38965189
PMC: 11315827.
DOI: 10.1007/s40268-024-00468-4.
N-acetyltransferase 10 facilitates tumorigenesis of diffuse large B-cell lymphoma by regulating AMPK/mTOR signalling through N4-acetylcytidine modification of SLC30A9.
Ding M, Yu Z, Lu T, Hu S, Zhou X, Wang X
Clin Transl Med. 2024; 14(7):e1747.
PMID: 38961519
PMC: 11222071.
DOI: 10.1002/ctm2.1747.
Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?.
Andres C, Perez de la Lastra J, Munguira E, Juan C, Perez-Lebena E
Int J Mol Sci. 2024; 25(11).
PMID: 38892287
PMC: 11172677.
DOI: 10.3390/ijms25116099.
Ibrutinib Modulates Proliferation, Migration, Mitochondrial Homeostasis, and Apoptosis in Melanoma Cells.
Lins F, Bispo E, Rodrigues N, Silva M, Carvalho J, Gelfuso G
Biomedicines. 2024; 12(5).
PMID: 38790974
PMC: 11117653.
DOI: 10.3390/biomedicines12051012.
Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock.
Minotti G
Blood Adv. 2024; 8(14):3810-3812.
PMID: 38696711
PMC: 11371468.
DOI: 10.1182/bloodadvances.2024013348.
New Means and Challenges in the Targeting of BTK.
Nawaratne V, Sondhi A, Abdel-Wahab O, Taylor J
Clin Cancer Res. 2024; 30(11):2333-2341.
PMID: 38578606
PMC: 11147694.
DOI: 10.1158/1078-0432.CCR-23-0409.
Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib.
Barragan A, Ghaby K, Pond M, Roux B
J Chem Inf Model. 2024; 64(8):3488-3502.
PMID: 38546820
PMC: 11386585.
DOI: 10.1021/acs.jcim.4c00023.
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Mouhssine S, Maher N, Matti B, Alwan A, Gaidano G
Int J Mol Sci. 2024; 25(6).
PMID: 38542207
PMC: 10970225.
DOI: 10.3390/ijms25063234.
